What is the appropriate management of Mycoplasma pneumoniae–associated mucositis?

Management of Mycoplasma pneumoniae-Associated Mucositis

Mycoplasma pneumoniae-associated mucositis (MPAM), also termed MIRM (Mycoplasma pneumoniae-induced rash and mucositis), requires macrolide antibiotics combined with systemic anti-inflammatory therapy, as the condition is driven more by inflammatory mechanisms than active infection. 1, 2

Clinical Recognition

MPAM is a distinct clinical entity characterized by:

• Severe mucositis affecting oral (100%), ocular (97%), and urogenital (78%) sites with minimal or absent cutaneous involvement 2
• Presentation typically 7-9 days after onset of respiratory symptoms (fever, cough) 2, 3
• Predominantly affects children and adolescents (median age 13.5 years), though adult cases occur 2, 4
• Falls within the Stevens-Johnson syndrome spectrum but represents a distinct phenotype with better prognosis 1, 5

Diagnostic Confirmation

• Confirm M. pneumoniae infection via IgM serology and/or PCR from respiratory specimens 2, 6
• Both tests should be ordered, as PCR provides rapid results while serology confirms diagnosis retrospectively 2

Treatment Algorithm

Antimicrobial Therapy

Macrolide antibiotics are essential despite the inflammatory nature of the disease:

• Azithromycin: 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg (max 250 mg) daily for days 2-5 7, 8, 5
• Alternative: Doxycycline 100 mg twice daily for 7-14 days in patients ≥8 years old 8, 6, 4
• Alternative: Levofloxacin 750 mg daily for adults (used successfully in case reports) 8, 4

Important caveat: Macrolides alone showed failure, relapse, or worsening in one-third of MPAM patients in case series, highlighting the need for concurrent anti-inflammatory therapy 2

Anti-Inflammatory Therapy

Systemic corticosteroids are the cornerstone of MPAM treatment, as the condition is primarily inflammatory:

• Prednisolone 1 mg/kg/day (or equivalent) should be initiated early in the disease course 5, 3, 4
• Duration typically 7-14 days with gradual taper based on clinical response 5, 4
• Corticosteroids were used in 31% of reported cases, though this likely underestimates optimal practice given the inflammatory pathogenesis 2

Alternative immunomodulatory options:

• Cyclosporine A (3-5 mg/kg/day) has shown rapid clinical resolution when initiated early, particularly in pediatric patients 3
• Intravenous immunoglobulin (IVIG) has been used in 9% of cases, though evidence is limited 2

Supportive Care

Aggressive supportive measures are critical:

• Pain management with systemic analgesics (opioids may be necessary for severe oral pain) 5, 3
• Intravenous hydration if oral intake is compromised 5, 4
• Meticulous mucosal care including oral rinses, ocular lubricants, and genital hygiene 2, 5
• Nutritional support via nasogastric tube if oral intake is severely limited 1

Clinical Pitfalls to Avoid

• Do not delay anti-inflammatory therapy while waiting for microbiological confirmation—the clinical phenotype (severe mucositis with minimal skin involvement and respiratory symptoms) is sufficient to initiate treatment 2, 5
• Do not rely on macrolides alone—the inflammatory component requires immunosuppression 2
• Do not assume treatment failure at 48-72 hours—mucositis may take several days to improve even with appropriate therapy 7, 8
• Do not confuse MPAM with drug-induced Stevens-Johnson syndrome—MPAM has a more favorable prognosis and different treatment approach 1, 5

Prognosis and Follow-Up

• MPAM has an excellent prognosis with complete resolution and no long-term sequelae in the vast majority of cases 2, 5
• Recurrence is rare 5
• Early ophthalmology consultation is warranted given the high rate of ocular involvement (97%), though permanent ocular complications are uncommon 1, 2
• Reassess at 48-72 hours for clinical improvement, but allow up to 2 weeks for complete mucosal healing 7, 6

Evidence Quality Considerations

The British Association of Dermatologists and UK guidelines recognize MPAM as a distinct clinical entity within the SJS/TEN spectrum 1. However, treatment recommendations are based primarily on case series and case reports rather than randomized trials 2, 5, 3, 4. The consistent finding across multiple case series that inflammatory mechanisms predominate supports the rationale for combining antimicrobials with immunosuppression 2, 5.